ClinicalTrials.gg
Active, not recruitingNCT04499248Updated May 22, 2026

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

A Phase 1/2 interventional study of AGN-193408 SR and Lumigan in Open-angle Glaucoma and Ocular Hypertension, sponsored by AbbVie. Active, not recruiting at 49 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by AbbVie · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 58 studies in Glaucoma, Open-Angle by AbbVie — 1 open to participants now, 3 under way, 1 of them phase 3. Glaucoma, Open-Angle · AbbVie.

Enrollment
27th of 34
100 · median 164
Started
2020
with 1 other
Phase 1/2
2 of 58
none open now
Registered
53rd of 58
by date

Among the 58 studies in Glaucoma, Open-Angle by AbbVie, this one is the 27th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2020, is one of 2 in phase 1/2, and was the 53rd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 58 studies in Glaucoma, Open-Angle by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Glaucoma, Open-Angle by AbbVie, or all of them as a file.
02

Study summary

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension

03

Conditions studied

  • Open-angle Glaucoma
  • Ocular Hypertension

Keywords

  • Open-angle glaucoma
  • Ocular hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is willing to withhold his/her IOP (Intraocular Pressure) treatments according to the study requirements, and in the opinion of the investigator, can do so without significant risk.
  • Diagnosis of either OAG [open-angle glaucoma] (ie, [POAG], pseudoexfoliation glaucoma,pigmentary glaucoma) or OHT (ocular hypertension) in both eyes.
  • Must be pseudophakic (at least 4 months postcataract surgery prior to treatment administration [Cycle 1 Day 1 Administration visit]) (Cohort 3 only).

Exclusion criteria

Exclusion Criteria:

  • Known allergy or sensitivity to any study medication or its components, any component of the delivery vehicle, procedure-related materials, or diagnostic agents used during the study (eg, topical anesthetic, dilating drops, fluorescein, povidone-iodine).
  • Concurrent or anticipated enrollment in an drug or device study or participation in such a study within 2 months prior to the Baseline visit through the final study visit.
  • History of intracameral implant in the study eye (eg, Bimatoprost SR, OTX-TIC, ENV515 Travoprost XR).
  • History of laser trabeculoplasty within 6 months prior to screening in the study eye.
  • History or evidence of , substantial ocular trauma (eg, a traumatic cataract, traumatic angle recession, etc.) in the study eye.
  • History or evidence of complicated cataract/lens surgery, as stated in the protocol.
  • Intraocular surgery (including cataract surgery) in the study eye within the 4 months prior to treatment administration.
  • Any history of corneal graft, including partial grafts (eg, Descemet's Stripping Endothelial Keratoplasty [DSEK], Descemet's Membrane Endothelial Keratoplasty [DMEK]); or incisional refractive surgery (eg, radial keratotomy), other than astigmatic keratotomy or limbal relaxing incisions in the study eye.
  • History of herpetic ocular diseases in either eye (including herpes simplex virus and varicella zoster virus).
  • Anticipated need for any incisional or laser ocular surgery in either eye during the study.
  • History of anatomically narrow angle resulting in evidence of angle changes or any history or closed angle glaucoma in the study eye.
  • History or evidence of a peripheral iridotomy/iridectomy in the inferior iris in the study eye.
  • Any history of trabeculectomy or other types of incisional glaucoma surgery, including a glaucoma seton or aqueous bypass stents in either eye, or minimally invasive glaucoma surgery (MIGS) type trabecular meshwork surgeries in the study eye.
  • Anticipated use of in either eye except for permitted interventions or systemically during the study, or historical use prior to Baseline within:

    • 3 years: intraocular fluocinolone acetonide
    • 6 months: intraocular corticosteroid(s) other than fluocinolone; any injectable periocular or sub-Tenon's/subconjunctival corticosteroid
    • 2 months: systemic (eg, oral, intramuscular, intravenous) or topical ocular corticosteroids
    • 2 weeks: dermal corticosteroids applied to skin of the eyelid(s), around the eye, or adnexa.
  • Anticipated use of other topical ocular medications in either eye except for permitted interventions.
  • The anticipated wearing of contact lenses in the study eye (Cohort 1) and both eyes (Cohorts 2 and 3) during the study that deviates from the following (contact lens wear is allowed during the study, but is to be temporarily discontinued before study visits, and before and after an Administration Day according to the following):

    • Use of soft lenses should be discontinued at least 3 days prior to Baseline, and use of rigid gas permeable or hard contact lenses should be discontinued at least 1 week prior to Baseline
    • Use of soft lenses should be discontinued at least 3 days and use of rigid gas permeable or hard contact lenses should be discontinued at least 1 week prior to a scheduled study visit or Administration Day visit
    • Use of contact lenses of any kind should be discontinued for 1 week following any AGN-193408 SR administration
  • Central corneal thickness of \< 480 or > 620 micrometers in both eyes.
  • Visual field loss in the study eye that, in the opinion of the investigator, is functionally significant (eg, split fixation, field defect within the central 10 degrees that is visually significant or likely to cause central visual impairment upon progression) or shows evidence of progressive visual field loss within the year prior to Baseline.
  • Evidence of macular edema in either eye during screening or in participant's medical history.
  • At Screening, evidence of posterior synechia behind the iris inferiorly in the study eye that in the investigator's opinion may inhibit the ability to safely receive at least 1 AGN-193408 SR implant (Cohort 3 only).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Cohort 1 -Dose A

    Single dose of AGN-193408 SR Dose A administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.

    Drug: AGN-193408 SR · Other: Lumigan

  • Experimental
    Cohort 1 - Dose B

    Single dose of AGN-193408 SR Dose B administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.

    Drug: AGN-193408 SR · Other: Lumigan

  • Experimental
    Cohort 2 - Dose A

    AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.

    Drug: AGN-193408 SR · Other: Lumigan · Other: Sham Administration · Other: Lumigan Vehicle

  • Experimental
    Cohort 2 - Dose B

    AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.

    Drug: AGN-193408 SR · Other: Lumigan · Other: Sham Administration · Other: Lumigan Vehicle

  • Experimental
    Cohort 3 - Dose A

    AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.

    Other: Lumigan · Drug: AGN-193408 SR · Other: Sham Administration · Other: Lumigan Vehicle

  • Experimental
    Cohort 3 - Dose B

    AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.

    Other: Lumigan · Drug: AGN-193408 SR · Other: Sham Administration · Other: Lumigan Vehicle

Interventions

  • DrugAGN-193408 SR

    An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.

  • OtherLumigan

    Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost

    Also known as: Active Comparator

  • OtherSham Administration

    Needleless applicator contacting similar intracameral insertion location on eye as AGN-193408 SR.

  • OtherLumigan Vehicle

    Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 2.

    Also known as: Vehicle

  • DrugAGN-193408 SR

    An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant in the study eye.

  • OtherSham Administration

    Needleless applicator contacting similar insertion location on eye as AGN-193408 SR.

  • OtherLumigan Vehicle

    Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 3.

    Also known as: Vehicle

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Hour 0 Intraocular Pressure (IOP) in the Study Eye

    IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

    Time frame: Baseline to Month 36

  2. Number of participants experiencing treatment emergent adverse events

    Time frame: Baseline to Month 36

Secondary outcomes

  1. Time to Rescue Treatment or Re-Treatment in the Study Eye

    Time to rescue treatment or the second treatment is defined as the time between the first treatment and the second treatment in the study eye.

    Time frame: Baseline to Month 36

07

Study locations

49 sites
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2020 (actual). Primary completion is estimated for Apr 2029, 101 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2020
First posted
Aug 5, 2020
StartActual
Nov 16, 2020
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2029
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04499248
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 5, 2020
Start date
Nov 16, 2020
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
May 22, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion